Nottingham major partner in a new Academic Liver Disease Network
Adverse liver reactions from medications are rare, but have serious consequences including life-threatening acute liver failure.
The European Cooperation in Science and Technology (COST) has launched a new network involving 51 partners across 16 Countries in Europe and worldwide to bring together scientists, clinicians, industry and regulators to focus on key challenges in this area.
Experts from diverse disciplines including drug development, clinical practice and medicines regulation have formed the Prospective European Drug-induced Liver Injury Network (Pro-Euro DILI). Professor Guruprasad Aithal, Gastrointestinal and Liver Disorder theme lead for the National Institute for Health Research Nottingham Biomedical Research Centre, is the Vice-Chair on the COST Action Management Committee. Dr Jane Grove, Assistant Professor at the Nottingham Digestive Diseases Centre, University of Nottingham is also the co-leader of one of the working groups. The new Network is chaired by Professor Raul Andrade, from the University of Malaga.
Professor Guruprasad Aithal said: “The Prospective European Drug-induced Liver Injury Network provides an excellent opportunity for scientists, clinicians, small and medium enterprises, pharma and regulators across Europe and beyond to get together and make co-ordinated efforts to address some of the most obdurate problems related to drug-induced liver injury.”
The new Network will host conferences, training schools and researcher exchange placements and promote a highly innovative and translational research programme striving to pre-empt and prevent Drug-Induced Liver Injury (DILI) over the next four years.